オプションチェーンは、Syndax Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Syndax Pharmaceuticalsの市場センチメントを評価します。.

Syndax Pharmaceuticals (NASDAQ:SNDX) 株価情報, オプションチェーン

Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
&nbsp;Niktimvo is the first and only FDA-approved prescription treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis.

News

INCY

SNDX

Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February

Scotiabank analyst George Farmer maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Sector Perform and lowers the price target from $18 to $16.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Lowers Price Target to $16

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64)&nbsp;show responses across all major subgroups, including heavily pretreated patients –
– 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort –
– 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML –
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –

Biotech

General

Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj

<ul>
<li>82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –</li>
<li>64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –</li>
<li>Responses were rapid, durable and observed across all major subgroups in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –</li>
<li>Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting –</li>
</ul>

Reported Saturday, Syndax's Revuforj (revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $33 to $38.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $38

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $37 to $45.

Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $45

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham boosted the price target for Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from $290 to $375. Needham analyst John Todaro maintained a Buy rating. Coinbase shares closed at $305.85 on Friday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) from $49 to $51. HC Wainwright &amp; Co. analyst Edward White maintained a Buy rating. Syndax Pharmaceuticals shares closed at $15.83 on Friday. <a href="https://www.benzinga.com/quote/SNDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) price target from $160 to $153. Morgan Stanley analyst Stephen Grambling maintained an Equal-Weight rating. Hyatt shares settled at $152.94 on Friday. <a href="https://www.benzinga.com/quote/H/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) price target from $18 to $5. HC Wainwright &amp; Co. analyst Amit Dayal maintained a Buy rating. Plug Power shares closed at $1.87 on Friday. <a href="https://www.benzinga.com/quote/PLUG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted Bel Fuse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) price target from $79 to $95. Needham analyst James Ricchiuti maintained a Buy rating. Bel Fuse shares closed at $74.56 on Friday.  <a href="https://www.benzinga.com/quote/BELFB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) price target from $70 to $90. Baird analyst Vikram Kesavabhotla upgraded the stock from Neutral to Outperform. Roku shares closed at $68.87 on Friday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $305 to $330. Baird analyst Joe Vruwink maintained an Outperform rating. Autodesk shares settled at $299.15 on Friday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted MBIA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) price target from $6.5 to $9. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith upgraded the stock from Market Perform to Outperform. MBIA shares closed at $6.03 on Friday. <a href="https://www.benzinga.com/quote/MBI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) from $10 to $6. B of A Securities analyst Tazeen Ahmad maintained a Neutral rating. PepGen shares closed at $4.12 on Friday. <a href="https://www.benzinga.com/quote/PEPG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted Assured Guaranty Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) price target from $92 to $105. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintained an Outperform rating. Assured Guaranty shares closed at $91.02 on Friday. <a href="https://www.benzinga.com/quote/AGO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ROKU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="561" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-1024x561.png" alt="" class="wp-image-652910" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-1024x561.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ADSK

BELFB

COIN

PEPG

PLUG

ROKU

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $49 to $51.

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CCLD

CCLDP

CERO

HRTX

LGMK

NGNE

NVRO

RMTI

STIM

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Tuesday,&nbsp;Syndax Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41896457/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-" rel="noreferrer noopener">trial of revumenib</a>.
The cohort met the primary endpoint with a complete remission (CR) plus CR with a partial hematological recovery (CRh) rate of 23% among the efficacy evaluable adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40396645/fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-" rel="noreferrer noopener">FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication</a>
Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.
At the data cutoff, the observed median duration of CR/CRh responses was 4.7 months, with three patients remaining in response.
Minimal residual disease (MRD) status was assessed in 14 of 15 patients who achieved CR/CRh, 64% (9/14) of whom were MRD negative. The overall response rate (ORR)&nbsp;was 47%.
17% of patients who achieved an overall response underwent hematopoietic stem cell transplant (HSCT) following treatment with revumenib, with three resuming revumenib therapy post-transplant.
The safety population included 84 adult and pediatric patients with R/R mNPM1 AML in the Phase 2 portion of the AUGMENT-101 trial.
The safety profile observed with revumenib in this population was consistent with previously reported data.
Treatment-related adverse events (TRAEs) leading to treatment discontinuations were 5%
The company is conducting several trials of revumenib across the treatment landscape in mNPM1 and KMT2A-rearranged (KMT2Ar) acute leukemias.
Syndax expects to achieve the following upcoming revumenib milestones:
<ul>
<li>Receive FDA approval for R/R KMT2Ar acute leukemias in the fourth quarter of 2024.</li>
<li>Initiate a pivotal combination trial with venetoclax/azacitidine in newly diagnosed mNPM1 AML or KMT2Ar acute leukemias by year-end 2024.</li>
<li>Publish pivotal AUGMENT-101 results in R/R mNPM1 AML patients and present results at a medical conference in the first half of 2025.</li>
<li>Submit a supplemental NDA for R/R mNPM1 AML in the first half of 2025.</li>
</ul>
Price Action: SNDX stock is down 22.1% at $16.96&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41912573/jp-morgan-sees-hope-for-home-depot-as-q3-decline-eases-2025-recovery-in-sight" target="_blank" rel="noreferrer noopener">Home Depot&#8217;s Earnings Beat Sets Conservative Tone for FY24, J.P. Morgan Predicts Slowing Deterioration Ahead</a></li>
</ul>

Health Care

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

HC Wainwright &amp; Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $47 to $49.

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $49

WIIM

Syndax Pharmaceuticals shares are trading lower. The company announced topline results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the Phase 2 portion of the AUGMENT-101 trial of revumenib.

<ul>
<li>Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014).</li>
<li>47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population.</li>
<li>Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events.</li>
<li>Results highlight consistency of revumenib's compelling clinical profile.</li>
<li>sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24</li>
</ul>

Syndax Pharmaceuticals Announced Topline Results From The Relapsed Or Refractory Mutant Npm1 Acute Myeloid Leukemia Cohort In The Phase 2 Portion Of The AUGMENT-101 Trial Of Revumenib

Goldman Sachs analyst Chris Shibutani maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $30 to $33.

Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $33

HC Wainwright &amp; Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $45 to $47.

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $47

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

Guidance

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

Earnings

Earnings Beats

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

– Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients –
WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), today announced that multiple abstracts evaluating Niktimvo&#x2122; (axatilimab-csfr), an anti-CSF-1R antibody for the treatment of chronic graft-versus-host disease (GVHD), have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 7-10, 2024. The presentations will highlight a secondary analysis of overall and organ-specific responses and findings from an exposure-response analysis in patients with chronic GVHD from the pivotal Phase 2 AGAVE-201 trial of Niktimvo, as well as preclinical data further characterizing the Niktimvo mechanism of action.

Syndax Announces New Data From Secondary Analysis Of The Pivotal AGAVE-201 Trial Of Niktimvo In Chronic Graft-Versus-Host Disease To Be Presented At 66th ASH Annual Meeting

Barclays analyst Peter Lawson assigned a Buy rating to Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $33.00. The ...

Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals ( ($SNDX) ) has shared an update. Syndax Pharmaceuticals has announced the elimination of the Chief Medical Officer position...

Syndax Pharmaceuticals Restructures Leadership Team

Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $33.00. Th...

Barclays Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)

Scotiabank lowered the firm's price target on Syndax (SNDX) to $16 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its ...

Syndax price target lowered to $16 from $18 at Scotiabank

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Syndax Pharmaceuticals (SNDX – Research Report), with a price targe...

Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research R...

Syndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America Securities

Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be avail...

Incyte, Syndax announce FDA approval for Niktimvo vial sizes

Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Kura Oncology: Sentiment Is Too Negative

KURA

KYKOF

RHHBY

RPRX

Press Releases

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors

Comments

Syndax Pharmaceuticals

Syndax Pharmaceuticals (SNDX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル